EUVIMEDEUVIMED entdecken
Crossref

Acalabrutinib alleviates metabolic dysfunction–associated steatotic liver disease by regulating bile acid metabolism

Yanbo Wang, Shiwei Chen, Bingjue Ye, Zhenggang Yang, Yanning Liu, Guohua Lou, Cheng Zhou, Min Zheng

The International Journal of Biochemistry & Cell Biology · 2025

DOI: 10.1016/j.biocel.2025.106786 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The International Journal of Biochemistry & Cell Biology, 2025. Verfasst von Yanbo Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical …. Hauptthemen laut MEDLINE: Benzamides, Bile Acids and Salts, Fatty Liver, Pyrazines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Zhejiang Provincial Ten Thousand Plan for Young Top Talents.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a global epidemic of chronic liver disease currently lacking effective treatment. Evaluating the therapeutic effects of existing drugs on MASLD is a time and cost-effective strategy. Bruton's tyrosine kinase (BTK) is an inflammatory signaling molecule playing an important role in the progression of MASLD. Aclabrutinib, a BTK inhibitor approved for treating mantle-cell lymphoma and chronic lymphocytic leukemia, has not been investigated for its potential to treat MASLD. This study examined the therapeutic effects and mechanisms of aclabrutinib on MASLD using a high-fat diet-induced mouse model. Results demonstrated significant alleviation of pathological parameters associated with MASLD upon administration of aclabrutinib. TSE PhenoMaster results revealed that aclabrutinib increased energy expenditure in mice. Furthermore, aclabrutinib upregulated the expression of genes associated with thermogenesis and lipolysis in adipose tissues. Additionally, it inhibited the transcription of genes related to lipid absorption in the small intestine and liver, while increasing the expression of hormone-sensitive lipase, hepatic nuclear factor 4 alpha and fibroblast growth factor 21 in the liver. Further analysis indicated that aclabrutinib promoted the alternative pathway of bile acid synthesis while restoring gut microbiota homeostasis. The altered bile acid profiles upregulated G protein-coupled bile acid receptor 1 expression in adipose tissues as well as vitamin D receptor expression in liver and small intestine. Our findings suggest that by regulating bile acid metabolism and gut microbiota, aclabrutinib may promote thermogenesis and lipolysis, thereby alleviating MASLD. This study provides novel insights into clinical applications targeting BTK for treating MASLD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BenzamidesBile Acids and SaltsFatty LiverPyrazinesNon-alcoholic Fatty Liver DiseaseAnimalsMiceMaleMice, Inbred C57BLDiet, High-FatDisease Models, AnimalLiverAgammaglobulinaemia Tyrosine Kinase

Stichwörter der Autor:innen

AcalabrutinibBile acid metabolismBruton's tyrosine kinaseGut microbiotaMetabolic dysfunction–associated steatotic liver disease

Substanzen

BenzamidesBile Acids and SaltsacalabrutinibPyrazinesAgammaglobulinaemia Tyrosine Kinase

Autor:innen und Institutionen

  • State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Di…

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Zhejiang Provincial Ten Thousand Plan for Young Top Talents
  • State Key Laboratory for Diagnosis and Treatment of Infectious Diseases
  • Key Research and Development Program of Zhejiang Province

Zitieren

APA

Wang, Y., Chen, S., Ye, B., Yang, Z., Liu, Y., Lou, G., Zhou, C., & Zheng, M. (2025). Acalabrutinib alleviates metabolic dysfunction–associated steatotic liver disease by regulating bile acid metabolism. The International Journal of Biochemistry & Cell Biology. https://doi.org/10.1016/j.biocel.2025.106786

Vancouver

Wang Y, Chen S, Ye B, Yang Z, Liu Y, Lou G, et al. Acalabrutinib alleviates metabolic dysfunction–associated steatotic liver disease by regulating bile acid metabolism. The International Journal of Biochemistry & Cell Biology. 2025. doi:10.1016/j.biocel.2025.106786

BibTeX
@article{Wang2025,
  author = {Wang, Yanbo and Chen, Shiwei and Ye, Bingjue and Yang, Zhenggang and Liu, Yanning and Lou, Guohua and Zhou, Cheng and Zheng, Min},
  title = {Acalabrutinib alleviates metabolic dysfunction–associated steatotic liver disease by regulating bile acid metabolism},
  journal = {The International Journal of Biochemistry & Cell Biology},
  year = {2025},
  doi = {10.1016/j.biocel.2025.106786}
}
Kostenlos starten →